Supporting Information

Ziyang Wang,^a Anqi Huang,^a Fang Fang,^b Pengfei Li,^{*b} Guokai Liu^{*c} and Wenjun Li^{*a}

^a Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, 266021, China

^b Department of Chemistry and Shenzhen Key Laboratory of Marine Archaea Geo-Omics, Southern University of Science and Technology, Shenzhen, 518055, China

^c School of Pharmaceutical Sciences, Shenzhen University Health Science Centre, Shenzhen University, Shenzhen, 518060, China

A: General Information and Starting Materials	2
B: General Procedure for 1,4-Addition	2
C: General Procedure for Synthesis of Starting Materials	3
D: Characterization Data	4
E: Large Scale Reaction	
F: Asymmetric Experiment	14
G: Control Experiments	16
H: NMR Analysis	
I: X-Ray Analysis Data	45
J: Reference	47

A: General Information and Starting Materials

General Information. Proton nuclear magnetic resonance (¹H NMR) spectra and carbon nuclear magnetic resonance (¹³C NMR) spectra were recorded on a Bruker ACF300 spectrometer (500 MHz and 125 MHz). Chemical shifts for protons are reported in parts per million downfield from tetramethylsilane and are referenced to residual protium in the NMR solvent (CDCl₃: δ 7.26; (CD₃)₂SO: δ 2.50). Chemical shifts for carbon are reported in parts per million downfield from tetramethylsilane and are referenced to the carbon resonances of the solvent (CDCl₃: δ 77.16; (CD₃)₂SO: δ 39.50). Data are represented as follows: chemical shift, integration, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants in Hertz (Hz). All high resolution mass spectra were obtained on a Finnigan/MAT 95XL-T mass spectrometer. For thin layer chromatography (TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, and compounds were visualized with a UV light at 254 nm. Flash chromatography separations were performed on Merck 60 (0.040-0.063 mm) mesh silica gel.

Starting Materials. All solvents, inorganic reagents were from commercial sources and used without purification unless otherwise noted. The *o*-hydroxyphenyl-substituted *p*-QMs and 5*H*-oxazol-4-ones were prepared following the literature procedures.¹⁻²

B: General Procedure for 1,4-Addition



To a solution of CH_2Cl_2 (0.3 mL) were added *ortho*-hydroxyphenyl substituted *p*-QMs **1** (0.05 mmol), 5*H*-oxazol-4-ones **2** (0.06 mmol) and catalyst **DBU** (0.001 mmol). The reaction mixture was stirred at 25 °C for 48 h and then the solvent was removed under vacuum. The residue was purified by silica gel chromatography to yield the desired product **3**.

C: General Procedure for Synthesis of Starting Materials Synthesis of *o*-hydroxyphenyl-substituted *p*-QMs¹



A solution of phenols (1.1 equiv.) and aldehydes (1.0 equiv.) in toluene (5 mL/mmol substrate) was placed in a Dean-Stark apparatus which was heated to reflux. Piperidine (2.0 equiv.) was added dropwise slowly. Then, the temperature was raised to 140 $^{\circ}$ C and stirred for 12 h. After that, the reaction mixture was cooled to 120 $^{\circ}$ C and acetic anhydride (2.0 equiv.) was dropwise added. The stirring was continued for 30 min and the solution was poured on ice-water and extracted with CH₂Cl₂ (3 × 50 mL). The organic phases were combined, washed with brine and dried over anhydrous Na₂SO₄. Then the solvent was evaporated under reduced pressure and the corresponding products were obtained after flash column chromatography (pentane/Et₂O = 100/1 to 30/1).

To a solution of product (1.0 equiv.) in THF (10 mL/mmol substrate) at 0 $^{\circ}$ C was added tetrabutylammonium fluoride trihydrate (1.1 equiv.). The reaction mixture was stirred for 10 min and a saturated NH₄Cl solution was added dropwise to quench the reaction. The resulting solution was extracted with Et₂O (3×20 mL). Then the combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed to give the crude product, which was purified by flash column chromatography (pentane/Et₂O = 10/1 to 4/1) to afford the desired compounds.

Synthesis of 5*H*-oxazol-4-ones²



To a solution/suspension of benzamide (1.0 equiv.) and pyridine (1.0 equiv.) in THF (0.8 M) was added α -haloacylchloride dropwise over 5 min at 0 °C. The resulting suspension was stirred overnight at rt and diluted with EtOAc. The mixture was acidified to pH=2 with 1N HCl aq. and the phases were separated. The aqueous phase was extracted with EtOAc and the combined organic layers were washed with water and brine, dried over Na₂SO₄, and filtered. Volatiles were removed under reduced pressure. The crude material was purified by either column chromatography on silica gel or recrystallization.

A suspension of K_2CO_3 in methyl *tert*-butylether (MTBE) was refluxed for 2 h to remove water using a Dean-Stark trap. The suspension was cooled to rt and animide was added in one portion. The resulting mixture was refluxed for the indicated time and cooled to room temperature. Inorganic salts were filtered through a celite pad

with suction and the filter cake was washed with EtOAc. The combined organic layers were concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to give the desired product.

D: Characterization Data

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-pheny loxazol-4(5*H*)-one (3aa)



White solid, 22.6 mg, 91% yield. mp 221.1-222.0 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.59 (s, 1H), 8.16-8.15 (m, 2H), 7.87 (d, *J* = 5.0 Hz, 1H), 7.81-7.78 (m, 1H), 7.65-7.62 (m, 2H), 7.11-7.07 (m, 1H), 6.97-6.94 (m, 1H), 6.92 (s, 1H), 6.83-6.81 (m, 1H), 6.65 (s, 1H), 4.86 (s, 1H), 1.91-1.86 (m, 1H), 1.81-1.76 (m, 1H), 1.07 (s, 18H), 0.66 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.2, 185.3, 155.4, 153.0, 138.8, 135.9, 130.1, 129.8, 128.6, 128.2, 126.3,

125.9, 125.6, 119.8, 116.0, 110.0, 94.6, 47.5, 34.6, 30.5, 27.8, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+(C_{32}H_{38}NO_4)$ requires m/z 500.2795, found m/z 500.2792.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-methyl-2-phe nyloxazol-4(5*H*)-one (3ab)



White solid, 29.5 mg, 99% yield. mp 181.2-181.9 °C. ¹H NMR (CDCl₃, 500 MHz): δ (ppm) 8.22 (d, J = 5.0 Hz, 2H), 7.94 (d, J = 10.0 Hz, 1H), 7.72-7.69 (m, 1H), 7.62 (d, J = 10.0 Hz, 1H), 7.57-7.54 (m, 2H), 7.21-7.18 (m, 1H), 7.10 (s, 2H), 7.07-7.04 (m, 1H), 7.01 (d, J = 10.0 Hz, 1H), 5.42 (s, 1H), 4.91 (s, 1H), 1.64 (s, 3H), 1.10 (s, 18H). ¹³C NMR (CDCl₃, 125 MHz): δ (ppm) 185.4, 154.5, 152.9, 135.3, 130.1, 129.1, 129.0, 128.1,

127.3, 127.3, 125.9, 125.8, 125.8, 120.3, 116.3, 110.0, 92.4, 48.5, 33.9, 29.9, 21.1. HRMS (ESI): exact mass calculated for $[M+H]^+(C_{31}H_{36}NO_4)$ requires m/z 486.2639, found m/z 486.2633.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-2-phenyl-5-prop yloxazol-4(5*H*)-one (3ac)



White solid, 21.7 mg, 85% yield. mp 218.9-221.8 °C. ¹H NMR $((CD_3)_2SO, 500 \text{ MHz}): \delta$ (ppm) 9.59 (s, 1H), 8.15 (d, J = 10.0 Hz, 2H), 7.88 (d, J = 5.0 Hz, 1H), 7.81-7.78 (m, 1H), 7.65-7.62 (m, 2H), 7.11-7.08 (m, 1H), 6.97-6.95 (m, 1H), 6.91 (s, 2H), 6.83-6.82 (m, 1H), 6.65 (s, 1H), 4.85 (s, 1H), 1.86-1.80 (m, 1H), 1.76-1.70 (m, 1H), 1.19-1.15 (m, 1H), 1.06 (s, 18H), 1.00-0.94 (m, 1H), 0.70 (t, J = 10.0 Hz, 3H). ¹³C NMR

((CD₃)₂SO, 125 MHz): δ (ppm) 193.3, 185.2, 155.4, 153.0, 138.7, 135.9, 130.1,

129.8, 129.2, 128.5, 128.2, 126.3, 125.9, 125.6, 119.8, 116.0, 94.3, 47.9, 36.7, 34.6, 30.5, 16.4, 14.2. HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₃₃H₄₀NO₄) requires m/z 514.2952, found m/z 514.2949.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-isopropyl-2-p henyloxazol-4(5*H*)-one (3ad)



White solid, 28.9 mg, 99% yield. mp 153.1-154.1 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.63 (s, 1H), 8.13 (d, J = 10.0 Hz, 2H), 7.93 (d, J = 10.0 Hz, 1H), 7.79-7.76 (m, 1H), 7.63-7.60 (m, 2H), 7.11-7.08 (m, 1H), 6.98-6.95 (m, 1H), 6.91 (s, 2H), 6.84 (d, J = 5.0 Hz, 1H), 6.62 (s, 1H), 5.01 (s, 1H), 2.31-2.26 (m, 1H), 1.06 (s, 18H), 1.02 (d, J = 10.0 Hz, 3H), 0.67 (d, J = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ

(ppm) 192.3, 184.9, 155.0, 152.9, 138.6, 135.8, 130.0, 129.7, 128.3, 128.2, 126.2, 126.0, 125.5, 119.6, 116.1, 96.4, 46.0, 34.6, 32.3, 30.5, 17.0, 14.7. HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₃₃H₄₀NO₄) requires m/z 514.2952, found m/z 514.2948.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-isobutyl-2-phe nyloxazol-4(5*H*)-one (3ae)



White solid, 25.8 mg, 98% yield. mp 219.2-221.5 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.57 (s, 1H), 8.14 (d, J = 10.0 Hz, 2H), 7.88 (d, J = 10.0 Hz, 1H), 7.81-7.78 (m, 1H), 7.65-7.62 (m, 2H), 7.11-7.07 (m, 1H), 6.98-6.95 (m, 1H), 6.88 (s, 2H), 6.82 (d, J = 5.0 Hz, 1H), 6.65 (s, 1H), 4.80 (s, 1H), 1.87-1.83 (m, 1H), 1.75-1.72 (m, 1H), 1.41-1.36 (m, 1H), 1.05 (s, 18H), 0.71 (d, J = 5.0 Hz, 6H). ¹³C NMR ((CD₃)₂SO, 125

MHz): δ (ppm) 193.5, 185.2, 155.5, 153.0, 138.7, 136.0, 130.0, 129.9, 128.3, 128.2, 126.5, 125.9, 125.7, 119.8, 116.0, 94.4, 49.0, 43.2, 34.6, 30.4, 24.6, 24.5, 23.7. HRMS (ESI): exact mass calculated for [M+H]⁺ (C₃₄H₄₂NO₄) requires m/z 528.3108, found m/z 528.3106.

5-benzyl-5-((3,5-di*-tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-2-phen yloxazol-4(5*H*)-one (3af)



White solid, 26.5 mg, 94% yield. mp 140.8-142.3 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.68 (s, 1H), 8.05 (d, *J* = 5.0 Hz, 1H), 8.01 (d, *J* = 5.0 Hz, 2H), 7.75-7.72 (m, 1H), 7.58-7.55 (m, 2H), 7.15-7.12 (m, 1H), 7.08-7.03 (m, 6H), 6.95 (s, 2H), 6.87 (d, *J* = 10.0 Hz, 1H), 6.67 (s, 1H), 5.01 (s, 1H), 3.20 (d, *J* = 15.0 Hz, 1H), 3.03 (d, *J* = 15.0 Hz, 1H), 1.06 (s, 18H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 192.3, 184.8, 155.6,

153.0, 138.8, 135.8, 134.1, 130.2, 129.8, 129.7, 129.2, 128.7, 128.4, 128.3, 127.5, 126.4, 125.9, 125.5, 120.0, 116.1, 94.1, 48.0, 34.6, 30.5. HRMS (ESI): exact mass

calculated for $[M+H]^+$ (C₃₇H₄₀NO₄) requires m/z 562.2952, found m/z 562.2947.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(4-fluo rophenyl)oxazol-4(5*H*)-one (3ag)



White solid, 22.7 mg, 88% yield. mp 229.1-230.7 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.60 (s, 1H), 8.26-8.23 (m, 2H), 7.87 (d, J = 10.0 Hz, 1H), 7.50-7.47 (m, 2H), 7.11-7.08 (m, 1H), 6.96-6.93 (m, 1H), 6.92 (s, 2H), 6.83 (d, J = 10.0 Hz, 1H), 6.67 (s, 1H), 4.87 (s, 1H), 1.92-1.87 (m, 1H), 1.81-1.77 (m, 1H), 1.09 (s, 18H), 0.67 (t, J = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ

(ppm) 193.0, 184.2, 166.9 (d, J = 1015.0 Hz), 155.4, 153.0, 138.8, 133.2 (d, J = 40.0 Hz), 129.2, 128.6, 128.2, 126.2, 125.8, 122.3, 119.7, 117.2 (d, J = 90.0 Hz), 116.0, 95.0, 60.2, 47.6, 34.6, 30.5, 27.8, 14.5, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+(C_{32}H_{37}FNO_4)$ requires m/z 518.2701, found m/z 518.2699.

2-(4-chlorophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ah)



White solid, 28.1 mg, 99% yield. mp 200.1-202.6 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.60 (s, 1H), 8.16 (d, *J* = 10.0 Hz, 2H), 7.85 (d, *J* = 5.0 Hz, 1H), 7.73(d, *J* = 5.0 Hz, 2H), 7.11-7.07 (m, 1H), 6.96-6.93 (m, 1H), 6.90 (s, 2H), 6.82 (d, *J* = 10.0 Hz, 1H), 6.67 (s, 1H), 4.86 (s, 1H), 1.91-1.86 (m, 1H), 1.80-1.76 (m, 1H), 1.08 (s, 18H), 0.66 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO,

125 MHz): δ (ppm) 193.0, 184.3, 155.4, 153.0, 140.9, 138.8, 131.8, 130.0, 129.2, 128.5, 128.2, 126.1, 125.8, 124.5, 119.7, 116.0, 95.0, 47.6, 34.6, 30.5, 27.7, 7.4. HRMS (ESI): exact mass calculated for [M+H]⁺ (C₃₂H₃₇ClNO₄) requires m/z 534.2406, found m/z 534.2405.

2-(4-bromophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ai)



White solid, 28.4 mg, 98% yield. mp 149.1-150.3 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.60 (s, 1H), 8.07 (d, J = 10.0 Hz, 2H), 7.87-7.84 (m, 3H), 7.11-7.08 (m, 1H), 6.96-6.93 (m, 1H), 6.90 (s, 2H), 6.83 (d, J = 5.0 Hz, 1H), 6.67 (s, 1H), 4.87 (s, 1H), 1.91-1.87 (m, 1H), 1.81-1.76 (m, 1H), 1.08 (s, 18H), 0.66 (t, J = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.1,

184.5, 155.4, 153.0, 138.8, 133.0, 131.8, 130.2, 129.2, 128.5, 128.2, 126.1, 125.8, 124.8, 119.7, 116.0, 95.0, 47.6, 34.6, 30.5, 27.7, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+(C_{32}H_{37}BrNO_4)$ requires m/z 578.1900, found m/z 578.1897.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(*p*-toly l)oxazol-4(5*H*)-one (3aj)



White solid, 27.9 mg, 99% yield. mp 231.9-233.2 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.58 (s, 1H), 8.05 (d, *J* = 5.0 Hz, 2H), 7.86 (d, *J* = 5.0 Hz, 1H), 7.45 (d, *J* = 5.0 Hz, 2H), 7.10-7.07 (m, 1H), 6.96-6.93 (m, 1H), 6.92 (s, 2H), 6.83-6.81 (m, 1H), 6.65 (s, 1H), 4.86 (s, 1H), 2.42 (s, 3H), 1.89-1.84 (m, 1H), 1.79-1.75 (m, 1H), 1.08 (s, 18H), 0.65 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO,

125 MHz): δ (ppm) 193.2, 185.2, 155.4, 153.0, 146.9, 138.7, 130.3, 130.1, 129.2, 128.8, 128.1, 126.4, 125.8, 122.9, 119.8, 116.0, 94.4, 47.5, 34.6, 30.5, 27.9, 21.9, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+(C_{33}H_{40}NO_4)$ requires m/z 514.2952, found m/z 514.2951.

2-(3-bromophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ak)



White solid, 28.2 mg, 98% yield. mp 150.2-152.3 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.60 (s, 1H), 8.21 (s, 1H), 8.15 (d, J = 10.0 Hz, 1H), 8.00 (d, J = 10.0 Hz, 1H), 7.85 (d, J = 10.0 Hz, 1H), 7.61-7.58 (m, 1H), 7.11-7.08 (m, 1H), 6.98-6.95 (m, 1H), 6.90 (s, 2H), 6.83 (d, J = 10.0 Hz, 1H), 6.68 (s, 1H), 4.87 (s, 1H), 1.94-1.89 (m, 1H), 1.82-1.77 (m, 1H), 1.09 (s, 18H),

0.68 (t, J = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.0, 184.0, 155.4, 153.0, 138.8, 138.5, 132.0, 132.0, 129.1, 128.3, 128.2, 127.8, 126.0, 125.9, 122.8, 119.8, 116.0, 110.0, 95.2, 47.7, 34.6, 30.4, 27.7, 7.4. HRMS (ESI): exact mass calculated for [M+H]⁺ (C₃₂H₃₇BrNO₄) requires m/z 578.1900, found m/z 578.1901.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(*m*-tol yl)oxazol-4(5*H*)-one (3al)



White solid, 31.2 mg, 99% yield. mp 143.2-145.1 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.59 (s, 1H), 7.96-7.95 (m, 2H), 7.87 (d, *J* = 5.0 Hz, 1H), 7.60 (d, *J* = 10.0 Hz, 1H), 7.53-7.49 (m, 1H), 7.11-7.07 (m, 1H), 6.98-6.95 (m, 1H), 6.93 (s, 2H), 6.84-6.82 (m, 1H), 6.65 (s, 1H), 4.87 (s, 1H), 2.40 (s, 3H), 1.90-1.86 (m, 1H), 1.80-1.76 (m, 1H), 1.08 (s, 18H), 0.66 (t, *J* = 10.0 Hz,

3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.2, 185.4, 155.4, 153.0, 139.3, 138.7, 136.5, 130.3, 129.7, 129.2, 128.6, 128.2, 127.3, 126.3, 125.9, 125.6, 119.8, 116.0, 94.6, 47.6, 34.6, 30.5, 27.8, 21.2, 7.4. HRMS (ESI): exact mass calculated for [M+H]⁺(C₃₃H₄₀NO₄) requires m/z 514.2952, found m/z 514.2952.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(3-met hoxyphenyl)oxazol-4(5*H*)-one (3am)



White solid, 32.8 mg, 99% yield. mp 180.2-182.5 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.60 (s, 1H), 7.84 (d, *J* = 10.0 Hz, 1H), 7.77 (d, *J* = 10.0 Hz, 1H), 7.58-7.55 (m, 2H), 7.38-7.36 (m, 1H), 7.10-7.07 (m, 1H), 6.97-6.94 (m, 1H), 6.92 (s, 2H), 6.83 (d, *J* = 5.0 Hz, 1H), 6.67 (s, 1H), 4.86 (s, 1H), 3.82 (s, 3H), 1.91-1.86 (m, 1H), 1.81-1.76 (m, 1H), 1.08 (s, 18H),

0.66 (t, J = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.2, 185.2, 156.0, 155.4, 153.0, 138.8, 131.1, 129.2, 128.6, 128.2, 126.9, 126.3, 125.9, 122.3, 121.9, 119.8, 116.0, 114.6, 94.8, 56.0, 47.6, 34.6, 30.5, 27.8, 7.4. HRMS (ESI): exact mass calculated for [M+H]⁺ (C₃₃H₄₀NO₅) requires m/z 530.2901, found m/z 530.2901.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(2-fluo rophenyl)oxazol-4(5*H*)-one (3an)



White solid, 28.2 mg, 99% yield. mp 190.1-192.2 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.60 (s, 1H), 8.08-8.04 (m, 1H), 7.85-7.82 (m, 2H), 7.53-7.49 (m, 1H), 7.44-7.41 (m, 1H), 7.10-7.07 (m, 1H), 6.93 (s, 2H), 6.92-6.91 (m, 1H), 6.83-6.82 (m, 1H) 6.69 (s, 1H), 4.87 (s, 1H), 1.90-1.85 (m, 1H), 1.81-1.76 (m, 1H), 1.09 (s, 18H), 0.68 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ

(ppm) 192.9, 183.4, 162.1 (d, J = 1045.0 Hz), 155.4, 153.0, 138.8, 138.3 (d, J = 35.0 Hz), 133.0, 129.0, 128.4, 128.2, 126.1, 125.8, 119.6, 118.1 (d, J = 85.0 Hz), 116.0, 113.8 (d, J = 30.0 Hz), 94.3, 47.4, 34.6, 30.5, 27.8, 7.4. HRMS (ESI): exact mass calculated for [M+H]⁺ (C₃₂H₃₇FNO₄) requires m/z 518.2701, found m/z 518.2700.

2-(2-chlorophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ao)



White solid, 21.8 mg, 82% yield. mp 145.9-147.5 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.59 (s, 1H), 8.01-7.99 (m, 1H), 7.82 (d, J = 5.0 Hz, 1H), 7.72-7.69 (m, 2H), 7.55-7.52 (m, 1H), 7.10-7.06 (m, 1H), 6.93-6.91 (m, 1H), 6.90 (s, 2H), 6.83-6.81 (m, 1H), 6.70 (s, 1H), 4.88 (s, 1H), 1.94-1.90 (m, 1H), 1.81-1.77 (m, 1H), 1.10 (s, 18H), 0.71 (t, J = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ

(ppm) 193.2, 184.7, 155.4, 153.1, 138.6, 136.2, 134.4, 133.7, 132.5, 129.2, 128.3, 128.2, 125.9, 125.8, 124.4, 119.6, 116.1, 94.8, 47.5, 34.6, 30.4, 27.8, 7.5. HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₃₂H₃₇ClNO₄) requires m/z 534.2406, found m/z 534.2405.

2-(2-bromophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ap)



 $((CD_3)_2SO, 125 \text{ MHz}): \delta$ (ppm) 193.2, 185.2, 155.4, 153.1, 138.6, 136.1, 135.9, 133.9, 129.3, 128.7, 128.2, 128.1, 126.3, 125.9, 122.6, 119.6, 116.1, 95.1, 47.5, 34.6, 30.5, 27.8, 7.6. HRMS (ESI): exact mass calculated for $[M+H]^+$ ($C_{32}H_{37}BrNO_4$) requires m/z 578.1900, found m/z 578.1902.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(5-fluoro-2-hydroxyphenyl)methyl)-5-ethyl -2-phenyloxazol-4(5*H*)-one (3ba)



^tBu

HO

White solid, 24.1 mg, 93% yield. mp 177.4-179.9 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.69 (s, 1H), 8.14 (d, *J* = 10.0 Hz, 2H), 7.81-7.78 (m, 1H), 7.66-7.63 (m, 2H), 7.58-7.55 (m, 1H), 6.98-6.94 (m, 1H), 6.89 (s, 2H), 6.84-6.81 (m, 1H), 6.72 (s, 1H), 4.84 (s, 1H), 1.93-1.89 (m, 1H), 1.83-1.79 (m, 1H), 1.07 (s, 18H), 0.68 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 192.8, 185.3, 155.8 (d, *J* = 935.0 Hz), 153.2, 151.8, 138.9, 136.0, 130.0 (d, *J* = 90.0 Hz), 127.9, 127.6 (d, *J* =

25.0 Hz), 125.7, 125.5, 116.8 (d, J = 35.0 Hz), 115.3, 115.1, 114.5 (d, J = 90.0 Hz), 94.3, 47.7, 34.6, 30.4, 27.8, 18.5, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₃₂H₃₇FNO₄) requires m/z 518.2701, found m/z 518.2700.

5-((5-chloro-2-hydroxyphenyl)(3,5-di-*tert*-butyl-4-hydroxyphenyl)methyl)-5-ethyl -2-phenyloxazol-4(5*H*)-one (3ca)



White solid, 23.4 mg, 88% yield. mp 140.1-141.7 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 10.02 (s, 1H), 8.10 (d, *J* = 5.0 Hz, 2H), 7.82-7.79 (m, 1H), 7.77-7.76 (m, 1H), 7.68-7.65 (m, 2H), 7.17-7.15 (m, 1H), 6.89 (s, 2H), 6.85 (d, *J* = 10.0 Hz, 1H), 6.74 (s, 1H), 4.83 (s, 1H), 1.91-1.87 (m, 1H), 1.84-1.79 (m, 1H), 1.07 (s, 18H), 0.68 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 192.7, 185.2, 154.4, 153.2, 139.0, 136.1, 129.9, 129.8, 128.7, 128.3, 128.0, 127.8, 125.7, 125.5, 123.0, 146.0 Solve a statement of the statement of the

117.6, 94.3, 47.5, 34.6, 30.4, 27.8, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+(C_{32}H_{37}CINO_4)$ requires m/z 534.2406, found m/z 534.2407.

5-((5-bromo-2-hydroxyphenyl)(3,5-di-tert-butyl-4-hydroxyphenyl)methyl)-5-ethyl

-2-phenyloxazol-4(5H)-one (3da)



White solid, 25.1 mg, 87% yield. mp 235.2-237.7 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 10.05 (s, 1H), 8.09-8.08 (m, 2H), 7.92-7.91 (m, 1H), 7.81-7.78 (m, 1H), 7.67-7.64 (m, 2H), 7.29-7.27 (m, 1H), 6.90 (s, 2H), 6.82 (d, *J* = 10.0 Hz, 1H), 6.74 (s, 1H), 4.84 (s, 1H), 1.91-1.87 (m, 1H), 1.85-1.80 (m, 1H), 1.08 (s, 18H), 0.69 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 192.7, 185.2, 154.8, 153.2, 139.0, 136.1, 131.7, 130.8, 129.9, 129.8, 128.8, 127.9, 125.7, 125.5, 118.2,

110.6, 94.3, 47.5, 34.6, 30.4, 27.8, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+(C_{32}H_{37}BrNO_4)$ requires m/z 578.1900, found m/z 578.1900.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxy-5-methylphenyl)methyl)-5-ethy l-2-phenyloxazol-4(5*H*)-one (3ea)



White solid, 29.6 mg, 99% yield. mp 134.2-136.6 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.37 (s, 1H), 8.14 (d, *J* = 5.0 Hz, 2H), 7.80-7.77 (m, 1H), 7.66-7.63 (m, 3H), 6.94 (s, 2H), 6.89 (d, *J* = 5.0 Hz, 1H), 6.73 (d, *J* = 5.0 Hz, 1H), 6.66 (s, 1H), 4.86 (s, 1H), 2.32 (s, 3H), 1.91-1.86 (m, 1H), 1.82-1.78 (m, 1H), 1.08 (s, 18H), 0.67 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.2, 185.2, 153.1, 153.0, 138.8, 135.9, 123.0, 129.8, 128.8, 128.5, 128.0, 126.0, 125.8, 125.6, 115.8, 94.7.

47.4, 34.6, 30.5, 27.8, 21.2, 14.5, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₃₃H₃₉NO₄) requires m/z 514.2952, found m/z 514.2951.

5-((4-bromo-2-hydroxyphenyl)(3,5-di*-tert*-butyl-4-hydroxyphenyl)methyl)-5-ethyl -2-phenyloxazol-4(5*H*)-one (3fa)



White solid, 25.3 mg, 88% yield. mp 207.0-208.3 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 10.19 (s, 1H), 8.17 (d, *J* = 5.0 Hz, 2H), 7.83-7.77 (m, 2H), 7.64-7.61 (m, 2H), 7.16-7.14 (m, 1H), 7.00-6.99 (m, 1H), 6.88 (s, 2H), 6.69 (s, 1H), 4.79 (s, 1H), 1.90-1.86 (m, 1H), 1.80-1.76 (m, 1H), 1.07 (s, 18H), 0.67 (t, *J* = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.0, 185.3, 156.7, 153.1,

138.9, 136.0, 130.9, 130.1, 129.8, 128.0, 126.0, 125.8, 125.5, 122.6, 120.4, 118.6, 94.2, 47.4, 34.6, 30.5, 27.8, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₃₂H₃₇BrNO₄) requires m/z 578.1900, found m/z 578.1902.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxy-4-methoxyphenyl)methyl)-5-et hyl-2-phenyloxazol-4(5*H*)-one (3ga)

White solid, 22.8 mg, 86% yield. mp 79.4-80.2 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ

(ppm) 9.65 (s, 1H), 8.15 (d, *J* = 10.0 Hz, 2H), 7.80-7.75 (m, 2H), 7.65-7.61 (m, 2H), 6.90 (s, 2H), 6.64 (s, 1H), 6.58-6.55 (m, 1H), 6.41-6.40 (m, 1H), 4.77 (s, 1H), 3.68 (s,



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxy-3-methylphenyl)methyl)-5-ethy l-2-phenyloxazol-4(5*H*)-one (3ha)



White solid, 23.2 mg, 92% yield. mp 223.1-224.5 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 8.46 (s, 1H), 8.15 (d, J = 5.0 Hz, 2H), 7.80-7.76 (m, 2H), 7.64-7.61 (m, 2H), 7.01 (d, J = 5.0 Hz, 1H), 6.94 (s, 2H), 6.92-6.91 (m, 1H), 6.64 (s, 1H), 4.99 (s, 1H), 2.16 (s, 3H), 1.93-1.89 (m, 1H), 1.82-1.78 (m, 1H), 1.07 (s, 18H), 0.66 (t, J = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.3, 185.2,

153.2, 153.0, 138.7, 135.9, 130.0, 129.8, 129.6, 128.7, 127.6, 126.7, 126.0, 125.6, 125.6, 120.2, 94.8, 48.1, 34.6, 30.5, 27.8, 17.6, 7.5. HRMS (ESI): exact mass calculated for $[M+H]^+(C_{33}H_{39}NO_4)$ requires m/z 514.2952, found m/z 514.2950.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxy-3-methoxyphenyl)methyl)-5-et hyl-2-phenyloxazol-4(5*H*)-one (3ia)



125 MHz): δ (ppm) 193.2, 185.3, 153.0, 148.0, 144.5, 138.8, 135.9, 130.0, 129.8, 128.6, 126.6, 125.9, 125.6, 120.9, 119.5, 110.4, 94.6, 56.1, 47.7, 34.6, 30.5, 27.8, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+$ ($C_{33}H_{40}NO_5$) requires m/z 530.2901, found m/z 530.2897.

5-((5-bromo-2-hydroxyphenyl)(3,5-di-*tert*-butyl-4-hydroxyphenyl)methyl)-5-met hyl-2-phenyloxazol-4(5*H*)-one (3db)

White solid, 27.3 mg, 99% yield. mp 166.4-168.8 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 10.05 (s, 1H), 8.07 (d, *J* = 5.0 Hz, 2H), 7.93-7.92 (m, 1H), 7.80-7.77 (m, 1H), 7.67-7.64 (m, 2H), 7.30-7.28 (m, 1H), 6.89 (s, 2H), 6.82 (d, *J* = 10.0 Hz, 1H), 6.74 (s,



1H), 4.79 (s, 1H), 1.45 (s, 3H), 1.08 (s, 18H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.4, 184.6, 155.0, 153.3, 139.0, 136.0, 131.7, 130.9 129.8, 128.7, 127.9, 125.8, 125.6, 118.2, 110.6, 90.7, 48.1, 34.6, 30.4, 21.2. HRMS (ESI): exact mass calculated for [M+H]⁺ (C₃₁H₃₅BrNO₄) requires m/z 564.1744, found m/z 564.1743.

E: Large Scale Reaction



To a solution of CH_2Cl_2 (12.0 mL) were added *ortho*-hydroxyphenyl substituted *p*-QMs **1a** (620.0 mg, 2.0 mmol), 5*H*-oxazol-4-one **2a** (453.6 mg, 2.4 mmol) and **DBU** (6.08 mg, 0.04 mmol). The reaction mixture was stirred at 25 °C for 48 h and then the solvent was removed under vacuum. The residue was purified by silica gel chromatography to yield the desired product **3aa** (910.2 mg, 91% yield, >20:1 dr).

F: Asymmetric Experiment



Cat.

To a solution of CH_2Cl_2 (0.3 mL) were added *ortho*-hydroxyphenyl substituted *p*-QMs **1a** (0.05 mmol), 5*H*-oxazol-4-ones **2a** (0.06 mmol) and chiral catalyst (0.005 mmol). The reaction mixture was stirred at 5 °C for 48 h and then the solvent was removed under vacuum. The residue was purified by silica gel chromatography to yield the desired product **3aa**.

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-pheny loxazol-4(5*H*)-one (3aa)



White solid, 17.0 mg, 68% yield. mp 221.1-222.0 °C. ¹H NMR ((CD₃)₂SO, 500 MHz): δ (ppm) 9.59 (s, 1H), 8.16-8.15 (m, 2H), 7.87 (d, J = 5.0 Hz, 1H), 7.81-7.78 (m, 1H), 7.65-7.62 (m, 2H), 7.11-7.07 (m, 1H), 6.97-6.94 (m, 1H), 6.92 (s, 1H), 6.83-6.81 (m, 1H), 6.65 (s, 1H), 4.86 (s, 1H), 1.91-1.86 (m, 1H), 1.81-1.76 (m, 1H), 1.07 (s, 18H), 0.66 (t, J = 10.0 Hz, 3H). ¹³C NMR ((CD₃)₂SO, 125 MHz): δ (ppm) 193.2, 185.3, 155.4, 153.0, 138.8,

135.9, 130.1, 129.8, 128.6, 128.2, 126.3, 125.9, 125.6, 119.8, 116.0, 110.0, 94.6, 47.5, 34.6, 30.5, 27.8, 7.4. HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₃₂H₃₈NO₄) requires m/z 500.2795, found m/z 500.2792. The enantiomeric excess was determined to be 0% by HPLC. [IA column, 254 nm, *n*-hexane:IPA = 90:10, 0.8 mL/min]: 7.7 min (major), 8.7 min (minor).



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-pheny loxazol-4(5*H*)-one (3aa)



G: Control Experiments



To a solution of CH_2Cl_2 (0.3 mL) were added *para*-quinone methides **4a** (14.7 mg, 0.05 mmol), 5*H*-oxazol-4-one **2a** (11.34 mg, 0.06 mmol) and **DBU** (0.15 mg, 0.001 mmol). The reaction mixture was stirred at 25 °C for 48 h and then the solvent was removed under vacuum. The residue was purified by silica gel chromatography to yield the desired product **5aa** (24.8 mg, 99% yield, 5:3 dr).

To a solution of CH_2Cl_2 (0.3 mL) were added TBS-protected quinone methides **4b** (21.2 mg, 0.05 mmol), 5*H*-oxazol-4-one **2a** (11.34 mg, 0.06 mmol) and **DBU** (0.15 mg, 0.001 mmol). The reaction mixture was stirred at 25 °C for 48 h and then the solvent was removed under vacuum. The residue was purified by silica gel chromatography to yield the desired product **5ba** (28.3 mg, 92% yield, 1:1 dr).

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(phenyl)methyl)-5-ethyl-2-phenyloxazol-4 (5*H*)-one (5aa)



Colourless oil, 24.8 mg, 99% yield. ¹H NMR (CDCl₃, 500 MHz): δ (ppm) 8.20-8.18 (m, 2H), 8.16-8.14 (m, 1.24H), 7.70-7.67 (m, 1.6H), 7.63 (d, J = 10.0 Hz, 2H), 7.55-7.51 (m, 3.2H), 7.42-7.39 (m, 3.2H), 7.33 (d, J = 10.0 Hz, 1.32H), 7.30-7.28 (m, 1H), 7.09-7.05 (m, 1.75H), 7.04 (s, 2H), 5.14 (s, 0.61H), 4.95 (s, 1H), 4.39 (s, 1H), 4.37 (s, 0.65H), 2.02-1.95 (m, 3.32H), 1.68 (s, 1H), 1.46 (s, 10.91H), 1.16 (s, 18H), 0.82-0.78

(m, 5.11H). ¹³C NMR (CDCl₃, 125 MHz): δ (ppm) 193.4, 185.5, 185.4, 152.9, 139.6, 138.2, 135.9, 135.3, 135.0, 134.9, 129.9, 129.7, 129.3, 129.1, 129.0, 128.9, 128.8, 128.3, 127.7, 127.1, 127.0, 125.8, 125.7, 94.9, 94.8, 57.5, 57.4, 34.4, 34.0, 30.3, 29.9, 28.4, 28.1, 7.5, 7.4. HRMS (ESI): exact mass calculated for [M+H]⁺ (C₃₂H₃₈NO₃) requires m/z 484.2852, found m/z 484.2846.

5-((2-((*tert*-butyldimethylsilyl)oxy)phenyl)(3,5-di-*tert*-butyl-4-hydroxyphenyl)met hyl)-5-ethyl-2-phenyloxazol-4(5*H*)-one (5ba)



Colourless oil, 28.3 mg, 92% yield. ¹H NMR (CDCl₃, 500 MHz): δ (ppm) 8.21-8.19 (m, 2H), 8.17-8.16 (m, 2H), 7.97-7.95 (m, 1H), 7.74-7.72 (m, 1H), 7.71-7.68 (m, 1H), 7.68-7.64 (m, 1H), 7.56-7.53 (m, 2H), 7.53-7.50 (m, 2H), 7.32 (s, 2H), 7.18-7.14 (m, 1H), 7.10-7.07 (m, 1H), 7.03 (s, 2H), 6.99-6.96 (m, 1H), 6.86-6.85 (m, 1H), 6.76-6.74 (m, 1H), 6.70-6.67 (m, 1H), 5.18 (s, 1H), 5.08 (s, 1H), 5.04 (s, 1H), 4.89

(s, 1H), 2.02-1.98 (m, 2H), 1.97-1.92 (m, 2H), 1.37 (s, 18H), 1.15 (s, 18H), 1.13 (s, 9H), 1.07 (s, 9H), 0.82 (t, J = 10.0 Hz, 3H), 0.78 (t, J = 10.0 Hz, 3H), 0.36 (s, 3H), 0.28 (s, 3H), 0.23 (s, 3H), 0.20 (s, 3H). ¹³C NMR (CDCl₃, 125 MHz): δ (ppm) 193.3, 192.4, 185.1, 184.8, 153.8, 152.9, 152.6, 152.6, 135.5, 134.9, 134.8, 130.1, 129.8, 129.7, 129.7, 129.6, 129.6, 128.9, 128.8, 127.7, 127.2, 126.3, 126.2, 126.0, 126.0, 120.9, 120.7, 118.7, 118.1, 95.3, 95.1, 48.2, 46.7, 34.3, 34.0, 30.2, 29.9, 29.5, 28.9, 27.7, 26.1, 26.0, 18.4, 18.4, 7.5, 7.4. HRMS (ESI): exact mass calculated for [M+H]⁺ (C₃₈H₅₂NO₄Si) requires m/z 614.3666, found m/z 614.3660.



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(phenyl)methyl)-5-ethyl-2-phenyloxazol-4 (5*H*)-one (5aa)





H: NMR Analysis

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-pheny loxazol-4(5*H*)-one (3aa)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-methyl-2-phe nyloxazol-4(5*H*)-one (3ab)



S21

5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-2-phenyl-5-prop yloxazol-4(5*H*)-one (3ac)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-isopropyl-2-p henyloxazol-4(5*H*)-one (3ad)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-isobutyl-2-phe nyloxazol-4(5*H*)-one (3ae)



5-benzyl-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-2-phen yloxazol-4(5*H*)-one (3af)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(4-fluo rophenyl)oxazol-4(5*H*)-one (3ag)



2-(4-chlorophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ah)



2-(4-bromophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ai)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(*p*-toly l)oxazol-4(5*H*)-one (3aj)



2-(3-bromophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ak)







5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(3-met hoxyphenyl)oxazol-4(5*H*)-one (3am)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)methyl)-5-ethyl-2-(2-fluo rophenyl)oxazol-4(5*H*)-one (3an)



2-(2-chlorophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ao)



2-(2-bromophenyl)-5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxyphenyl)meth yl)-5-ethyloxazol-4(5*H*)-one (3ap)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(5-fluoro-2-hydroxyphenyl)methyl)-5-ethyl -2-phenyloxazol-4(5*H*)-one (3ba)



5-((5-chloro-2-hydroxyphenyl)(3,5-di-*tert*-butyl-4-hydroxyphenyl)methyl)-5-ethyl -2-phenyloxazol-4(5*H*)-one (3ca)



5-((5-bromo-2-hydroxyphenyl)(3,5-di-*tert*-butyl-4-hydroxyphenyl)methyl)-5-ethyl -2-phenyloxazol-4(5*H*)-one (3da)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxy-5-methylphenyl)methyl)-5-ethy l-2-phenyloxazol-4(5*H*)-one (3ea)



5-((4-bromo-2-hydroxyphenyl)(3,5-di-*tert*-butyl-4-hydroxyphenyl)methyl)-5-ethyl -2-phenyloxazol-4(5*H*)-one (3fa)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxy-4-methoxyphenyl)methyl)-5-et hyl-2-phenyloxazol-4(5*H*)-one (3ga)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxy-3-methylphenyl)methyl)-5-ethy l-2-phenyloxazol-4(5*H*)-one (3ha)



5-((3,5-di-*tert*-butyl-4-hydroxyphenyl)(2-hydroxy-3-methoxyphenyl)methyl)-5-et hyl-2-phenyloxazol-4(5*H*)-one (3ia)



5-((5-bromo-2-hydroxyphenyl)(3,5-di-*tert*-butyl-4-hydroxyphenyl)methyl)-5-met hyl-2-phenyloxazol-4(5*H*)-one (3db)



I: X-Ray Analysis Data



•	
Identification code	3db
Empirical formula	$C_{31}H_{34}BrNO_4$
Formula weight	564.50
Temperature/K	100
Crystal system	monoclinic
Space group	P2 ₁ /c
a/Å	10.805(2)
b/Å	28.766(4)
c/Å	9.1158(16)
$\alpha/^{\circ}$	90
β/°	98.138(6)
$\gamma^{/\circ}$	90
Volume/Å ³	2804.7(9)
Ζ	4
$\rho_{calc}g/cm^3$	1.337
μ/mm^{-1}	1.501
F(000)	1176.0
Crystal size/mm ³	0.48 imes 0.45 imes 0.39
Radiation	MoKa ($\lambda = 0.71073$)
2Θ range for data collection/ $^{\circ}$	² 4.73 to 55.118
Index ranges	$\text{-13} \leq h \leq 14, \text{-37} \leq k \leq 37, \text{-11} \leq l \leq 10$
Reflections collected	43790
Independent reflections	6427 [$R_{int} = 0.0548$, $R_{sigma} = 0.0324$]
Data/restraints/parameters	6427/3/344
Goodness-of-fit on F ²	1.047
Final R indexes $[I \ge 2\sigma(I)]$	$R_1 = 0.0333, wR_2 = 0.0734$
Final R indexes [all data]	$R_1 = 0.0399, wR_2 = 0.0758$
Largest diff. peak/hole / e Å-3	3 0.63/-0.72

Table 1 Crystal data and structure refinement.

J: Reference

- 1. K. Zhao, Y. Zhi, T. Shu, A. Valkonen, K. Rissanen, D. Enders, *Angew. Chem. Int. Ed.* **2016**, *55*, 12104-12108.
- 2. B. M. Trost, K. Hirano, Angew. Chem. Int. Ed. 2012, 51, 6480-6483.